Scholarlink

<p>This preclinical study aims to evaluate the antiarthritic and therapeutic efficacy of farnesol in a model of Freund’s complete adjuvant (FCA)-induced arthritis. Farnesol was administered orally once daily for 15&#xa0;days at doses of 50&#xa0;mg/kg, 100&#xa0;mg/kg, and 200&#xa0;mg/kg in 5% DMSO. Methotrexate (MTX) at 0.75&#xa0;mg/kg was used as a standard treatment, both alone and in combination with 200&#xa0;mg/kg farnesol. Hematological tests, paw thickness, body weight, and antioxidative status were measured to assess the protective effects of farnesol. Farnesol significantly increased the enzymatic activity of catalase (CAT) and superoxide dismutase (SOD), as well as the non-enzymatic activity of glutathione (GSH). In addition, farnesol reduced tissue lipid peroxidation and nitric oxide (NO) synthetase activity, which was evident by the reduced levels of oxidative stress markers malondialdehyde (MDA), asymmetric dimethylarginine (ADMA), and nitrite. Farnesol downregulated inflammatory markers, including dimethylarginine dimethylaminohydrolase 1 (DDAH 1), cortistatin (CST), interleukin-6 (IL-6), IL-1β, and tumor necrosis factor (TNF-α), in a dose-dependent manner. These findings suggest that oral administration of farnesol, particularly in combination with MTX, effectively suppresses FCA-induced arthritis by ameliorating oxidative stress and inflammatory markers.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Farnesol alleviates inflammatory responses and oxidative stress in Freund’s complete adjuvant induced arthritic rat model and associated risk factors of atherosclerosis

  • 期刊论文

  • 发表日期：

    2025年5月29日

查看全文
  • Isma Anwar,
  • Ali Sharif,
  • Mushtaq Ahmad,
  • Maryam Shabbir,
  • Bushra Akhtar

摘要

This preclinical study aims to evaluate the antiarthritic and therapeutic efficacy of farnesol in a model of Freund’s complete adjuvant (FCA)-induced arthritis. Farnesol was administered orally once daily for 15 days at doses of 50 mg/kg, 100 mg/kg, and 200 mg/kg in 5% DMSO. Methotrexate (MTX) at 0.75 mg/kg was used as a standard treatment, both alone and in combination with 200 mg/kg farnesol. Hematological tests, paw thickness, body weight, and antioxidative status were measured to assess the protective effects of farnesol. Farnesol significantly increased the enzymatic activity of catalase (CAT) and superoxide dismutase (SOD), as well as the non-enzymatic activity of glutathione (GSH). In addition, farnesol reduced tissue lipid peroxidation and nitric oxide (NO) synthetase activity, which was evident by the reduced levels of oxidative stress markers malondialdehyde (MDA), asymmetric dimethylarginine (ADMA), and nitrite. Farnesol downregulated inflammatory markers, including dimethylarginine dimethylaminohydrolase 1 (DDAH 1), cortistatin (CST), interleukin-6 (IL-6), IL-1β, and tumor necrosis factor (TNF-α), in a dose-dependent manner. These findings suggest that oral administration of farnesol, particularly in combination with MTX, effectively suppresses FCA-induced arthritis by ameliorating oxidative stress and inflammatory markers.